<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Greef, W.J. de</title>
    <link>http://repub.eur.nl/res/aut/4148/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in humans (Article)</title>
      <link>http://repub.eur.nl/res/pub/8717/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>TRH-like peptides have been identified that differ from TRH
          (pGlu-His-ProNH2) in the middle amino acid. We have estimated TRH-like
          immunoreactivity (TRH-LI) in human serum and urine by RIA with
          TRH-specific antiserum 8880 or with antiserum 4319, which binds most
          peptides with the structure pGlu-X-ProNH2. TRH was undetectable in serum
          (&lt; 25 pg/mL), but TRH-LI was detected with antiserum 4319 in serum of 27
          normal subjects, 21 control patients, and 12 patients with carcinoid
          tumors (range 17-45, 5-79, and 18-16,600 pg/mL, respectively). Because
          serum was kept for at least 2 h at room temperature, which causes
          degradation of TRH, pGlu-Phe-ProNH2, and pGlu-Tyr-ProNH2, serum TRH-LI is
          not caused by these peptides. On high-performance liquid chromatography,
          serum TRH-LI coeluted with pGlu-Glu-ProNH2 (&lt; EEP-NH2), a peptide produced
          in, among others, the prostate. Urine of normals and control patients also
          contained TRH-LI (range 1.14-4.97 and 0.24-5.51 ng/mL, respectively), with
          similar levels in males and females. TRH represented only 2% of urinary
          TRH-LI, and anion-exchange chromatography and high-performance liquid
          chromatography revealed that most TRH-LI in urine was &lt; EEP-NH2. In
          patients with carcinoid tumors, increased urinary TRH-LI levels were noted
          (range 1.35-962.4 ng/mL). Urinary TRH-LI correlated positively with
          urinary creatinine, and the urinary clearance rate of TRH-LI was similar
          to the glomerular filtration rate. In addition, serum TRH-LI was increased
          in 17 hemodialysis patients (43-373 pg/mL). This suggests that serum &lt;
          EEP-NH2 is cleared by glomerular filtration with little tubular
          resorption. The possible role of the prostate as a source of urinary
          TRH-LI was evaluated in 11 men with prostate cancer, showing a 25%
          decrease in urinary TRH-LI excretion after prostatectomy (0.19 +/- 0.02
          vs. 0.15 +/- 0.01 ng/mumol creatinine, mean +/- SEM). However, TRH-LI was
          similar in spontaneously voided urine and in urine obtained through a
          nephrostomy cannula from 16 patients with unilateral urinary tract
          obstruction (0.15 +/- 0.01 vs. 0.14 +/- 0.01 ng/mumol creatinine). These
          data indicate that: 1) TRH-LI in human serum represents largely &lt; EEP-NH2,
          which is cleared by renal excretion; 2) part of urinary &lt; EEP-NH2 is
          derived from prostatic secretion into the blood and not directly into
          urine; and 3) urinary &lt; EEP-NH2 can be used as marker for carcinoid
          tumors.</description>
    </item> <item>
      <title>Characterization of iodothyronine sulfotransferase activity in rat liver (Article)</title>
      <link>http://repub.eur.nl/res/pub/8731/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Sulfation is an important pathway in the metabolism of thyroid hormone
      because it strongly facilitates the degradation of the hormone by the type
      I iodothyronine deiodinase. However, little is known about the properties
      and possible regulation of the sulfotransferase(s) involved in the
      sulfation of thyroid hormone. We have developed a convenient method for
      the analysis of iodothyronine sulfotransferase activity in tissue
      cytosolic fractions, using radioiodinated 3,3'-diiodothyronine (3,3'-T2)
      as the preferred substrate, unlabeled
      3'-phosphoadenosine-5'-phosphosulfate (PAPS) as the sulfate donor, and
      Sephadex LH-20 minicolomns for separation of the products. We found that
      iodothyronine sulfotransferase activity in rat liver cytosol is 1) higher
      in male than in female rats; 2) optimal at pH 8.0; 3) characterized (at 50
      microM PAPS and pH 7.2) by apparent Michaelis-Menton (Km) values for
      3,3'-T2 of 1.77 and 4.19 microM, and Vmax values of 1.94 and 1.45 nmol/min
      per mg protein in male and female rats, respectively; 4) characterized (at
      1 microM 3,3'-T2 and pH 7.2) by apparent Km values for PAPS of 4.92 and
      3.80 microM and Vmax values of 0.72 and 0.31 nmol/min per mg protein, in
      males and females, respectively; 5) little affected by hyperthyroidism in
      both male and female rats, but significantly decreased by hypothyroidism
      in males but not in females; and 6) not affected by short-term (3 days)
      fasting in both male and female rats, but significantly decreased by
      long-term (3 weeks) food restriction to one-third of normal intake in
      males but not in females. It is suggested that the higher hepatic
      iodothyronine sulfotransferase activity in male vs. female rats, as well
      as the decreases induced in males by hypothyroidism and long-term food
      restriction, represents differences in the expression of the male-dominant
      isoenzyme rSULT1C1.</description>
    </item> <item>
      <title>Evidence that the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in human serum may not be secreted by the pituitary gland (Article)</title>
      <link>http://repub.eur.nl/res/pub/8740/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Recent studies have revealed that TRH-like immunoreactivity (TRH-LI) in
          human serum is predominantly pGlu-Glu-ProNH2 (&lt; EEP-NH2), a peptide
          previously found in, among others tissues, the pituitary gland of various
          mammalian species. In the rat pituitary, &lt; EEP-NH2 is present in
          gonadotrophs and its pituitary content is regulated by gonadal steroids
          and gonadotrophin-releasing hormone (GnRH). Hence, we reasoned that &lt;
          EEP-NH2 in human serum may also arise, at least in part, from the
          pituitary, and that its secretion may correlate with that of
          gonadotrophins. Therefore, blood was simultaneously sampled from both
          inferior petrosal sinuses, which are major sites of the venous drainage of
          the pituitary gland, and a peripheral vein from seven patients with
          suspected adrenocorticotrophin-secreting pituitary tumours. In addition,
          in six postmenopausal and six cyclic women, peripheral vein blood was
          collected at 10-min intervals for 6 h, then a standard 100 micrograms GnRH
          test was performed. In the sera, TRH-LI was estimated by RIA with
          antiserum 4319, which binds most tripeptides that share the N- and
          C-terminal amino acids with TRH (pGlu-His-ProNH2). In addition, LH and FSH
          were measured in these sera by RIA. In the blood samples taken at 10-min
          intervals, an episodic variation in serum TRH-LI was noted and pulses of
          TRH-LI were detected at irregular intervals (from one to six pulses per 6
          h) in five postmenopausal and six cyclic women. In general, these pulses
          did not coincide with those of LH and FSH, suggesting that TRH-LI is not
          co-secreted with gonadotrophins. Moreover, unlike LH and FSH, serum TRH-LI
          did not increase during the menopause or after exogenous administration of
          GnRH. Whereas gonadotrophin concentrations were significantly greater in
          the inferior petrosal sinus than in peripheral serum, there were no
          differences in TRH-LI concentrations between these serum samples. In
          conclusion, serum TRH-LI in humans seems not to be regulated by gonadal
          steroids or GnRH. Moreover, serum derived directly from the pituitary
          contained no more TRH-LI than did peripheral serum, which suggests that
          the human pituitary gland does not secrete significant amounts of &lt;
          EEP-NH2, and therefore does not contribute significantly to serum TRH-LI
          concentrations. Further research is required to identify the site of
          origin of &lt; EEP-NH2 in human serum.</description>
    </item> <item>
      <title>Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis (Article)</title>
      <link>http://repub.eur.nl/res/pub/8570/</link>
      <pubDate>1994-01-01T00:00:00Z</pubDate>
      <description>The cytokines interleukin-1 (IL-1) and IL-6 are thought to be important
          mediators in the suppression of thyroid function during nonthyroidal
          illness. In this study we compared the effects of IL-1 and IL-6 infusion
          on the hypothalamus-pituitary-thyroid axis in rats. Cytokines were
          administered by continuous ip infusion of 4 micrograms IL-1 alpha/day for
          1, 2, or 7 days or of 15 micrograms IL-6/day for 7 days. Body weight and
          temperature, food and water intake, and plasma TSH, T4, free T4 (FT4), T3,
          and corticosterone levels were measured daily, and hypothalamic pro-TRH
          messenger RNA (mRNA) and hypophysial TSH beta mRNA were determined after
          termination of the experiments. Compared with saline-treated controls,
          infusion of IL-1, but not of IL-6, produced a transient decrease in food
          and water intake, a transient increase in body temperature, and a
          prolonged decrease in body weight. Both cytokines caused transient
          decreases in plasma TSH and T4, which were greater and more prolonged with
          IL-1 than with IL-6, whereas they effected similar transient increases in
          the plasma FT4 fraction. Infusion with IL-1, but not IL-6, also induced
          transient decreases in plasma FT4 and T3 and a transient increase in
          plasma corticosterone. Hypothalamic pro-TRH mRNA was significantly
          decreased (-73%) after 7 days, but not after 1 or 2 days, of IL-1 infusion
          and was unaffected by IL-6 infusion. Hypophysial TSH beta mRNA was
          significantly decreased after 2 (-62%) and 7 (-62%) days, but not after 1
          day, of IL-1 infusion and was unaffected by IL-6 infusion. These results
          are in agreement with previous findings that IL-1, more so than IL-6,
          directly inhibits thyroid hormone production. They also indicate that IL-1
          and IL-6 both decrease plasma T4 binding. Furthermore, both cytokines
          induce an acute and dramatic decrease in plasma TSH before (IL-1) or even
          without (IL-6) a decrease in hypothalamic pro-TRH mRNA or hypophysial TSH
          beta mRNA, suggesting that the acute decrease in TSH secretion is not
          caused by decreased pro-TRH and TSH beta gene expression. The
          TSH-suppressive effect of IL-6, either administered as such or induced by
          IL-1 infusion, may be due to a direct effect on the thyrotroph, whereas
          additional effects of IL-1 may involve changes in the hypothalamic release
          of somatostatin or TRH.(ABSTRACT TRUNCATED AT 400 WORDS)</description>
    </item> <item>
      <title>Experimenten betreffende de activiteit van het corpus luteum bij de pseudozwangere rat (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/25995/</link>
      <pubDate>1976-11-24T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>